Document is current

Article History

Accepted: 2 February 2025

First Online: 27 February 2025

Declarations

:

: R.R., E. Russo, and S.L. contributed to the study conception and design. Data collection was performed by V.C., A.D.A., C.D.B., Giancarlo D.G., F.F., E.F., A.M., A.P. E. Rosati, and I.S.; data analysis was performed by R.R. and Gianfranco D.G. The first draft of the manuscript was written by R.R., Gianfranco D.G., E. Russo, and S.L. and all authors commented on previous versions of the manuscript. All authors read and approved of the final manuscript.

: Open access funding provided by Università degli studi "Magna Graecia" di Catanzaro within the CRUI-CARE Agreement. Open Access fee was funded by University Magna Grecia of Catanzaro. This research was supported by an unconditional grant from Angelini Pharma.

: R.R. has received consultancy fees from Eisai. A.D. has participated in pharmaceutical industry-sponsored clinical trials for UCB Pharma, has received speaker honoraria from Eisai, UCB, Angelini Pharma, and Neuraxpharm, and has served on advisory boards for Angelini Pharma. C.D.B. has received consulting fees and honoraria from GW Pharmaceuticals, UCB Pharma, Eisai, Angelini Pharma, and Bial outside the submitted work. Giancarlo D.G. has participated on advisory boards and pharmaceutical industry-sponsored symposia for UCB Pharma, Eisai, BIAL, Lusofarmaco, LivaNova, Arvelle, and Angelini Pharma. E. Rosati has received consultancy fees from Angelini, UCB, Jazz Ph, Ecupharma, and Eisai. E. Russo has received speaker fees or funding from and has participated in advisory boards for Arvelle Therapeutics, Angelini Pharma, Eisai, Pfizer, GW Pharmaceuticals, Jazz Pharmaceuticals, UCB, and Lundbeck. S.L. has received speaker’s or consultancy fees from Angelini Pharma, Eisai, GW Pharmaceuticals, Medscape, and UCB Pharma and has served on advisory boards for Angelini Pharma, Arvelle Therapeutics, BIAL, Eisai, and GW Pharmaceuticals outside the submitted work. S.L. received research grant support from the Ministry of Health and the Ministry of University and Research outside the submitted work. The remaining authors have no conflicts of interest. S.L. is an Editorial Board member of CNS Drugs. S.L. was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.

: The overall, anonymized data collection was approved by the Ethics Committee of Calabria Region, Italy (protocol number 416/20) and conducted in accordance with the Declaration of Helsinki.

: The data that support the findings of this study are available from the corresponding author upon reasonable request.

: All patients provided written informed consent to participate in the study.

: Not applicable.

: Not applicable.